Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Oncology Research > Melanoma

Melanoma Research Reagents

Melanoma has become the paradigm for immune checkpoint therapy, with BRAF/MEK-targeted and PD-1/CTLA-4-based combination regimens transforming patient outcomes. abinScience provides antibodies, recombinant proteins, and assay kits spanning BRAF, MAPK pathway, melanocyte-lineage diagnostic markers (S100, gp100/PMEL, Melan-A), and the full spectrum of immune checkpoint targets. RUO

Key Biomarkers & Targets

BRAF
V600E/V600K
BRAF V600 mutations present in ~50% of cutaneous melanomas. Target of vemurafenib and dabrafenib. 79 antibodies for mutation-associated signaling studies.
Antibodies
PD-1 / PD-L1
CD279 / CD274
First cancer type where anti-PD-1 (nivolumab, pembrolizumab) achieved durable responses. 260+ combined antibodies, proteins, and biosimilars.
Antibodies • Proteins • Biosimilars
CTLA-4
CD152
Ipilimumab (anti-CTLA-4) was the first checkpoint inhibitor approved in melanoma. 144 products for combination immunotherapy studies.
Antibodies • Proteins • Biosimilars
LAG-3 / TIGIT / TIM-3
Next-Gen Checkpoints
Emerging immune checkpoints under active clinical investigation in melanoma (relatlimab + nivolumab). 125+ combined products.
Antibodies • Proteins • Biosimilars
gp100 / PMEL
Melanocyte Antigen
Melanoma-associated antigen; target of tebentafusp (bispecific gp100×CD3). 20 antibodies for tumor antigen detection and T-cell assay development.
Antibodies • Biosimilars
S100
S100B / S100A4
Classic IHC diagnostic marker for melanocytic lesions. Serum S100B used for monitoring metastatic disease progression. 41 products.
Antibodies • Proteins

Why Researchers Choose abinScience for Melanoma

MAPK Pathway Depth BRAF → MEK → ERK signaling cascade covered end-to-end. Antibodies for studying resistance mechanisms to BRAF/MEK inhibitor combinations.
Complete Checkpoint Portfolio PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3, IDO1 — the most comprehensive immune checkpoint reagent set for melanoma immuno-oncology research.
Melanocyte-Lineage Diagnostics S100, gp100/PMEL, Melan-A/MART-1, MITF, SOX10, tyrosinase — a full panel for melanoma diagnosis and differentiation from other malignancies.
Bispecific & TCR-T Reference gp100–peptide/HLA-A2 complex antibodies and tebentafusp biosimilar for next-generation bispecific and TCR-based therapy development.
Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

  1. BRAF/MEK resistance profiling: Use BRAF, MEK1/2, and phospho-ERK antibodies (WB, IHC) to characterize acquired resistance mechanisms in melanoma cell lines and PDX models.
  2. Immune checkpoint combination screening: Evaluate PD-1 + CTLA-4, PD-1 + LAG-3, and other dual-blockade strategies with recombinant checkpoint proteins in reporter cell-based assays.
  3. Melanoma vs. non-melanoma differential diagnosis: Apply our S100, SOX10, gp100, and Melan-A antibodies in IHC panels to distinguish melanoma from poorly differentiated carcinoma and other spindle-cell tumors.
  4. Neoantigen & TCR-T development: Use our gp100/HLA-A2 complex reagents and IDO1 proteins for T-cell activation assays, antigen-specific killing, and tumor immune evasion studies.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry BRAF V600E mutation-specific antibodies?

Our anti-BRAF antibodies detect total BRAF protein. For V600E-specific detection, we recommend combining our BRAF antibodies (WB) with mutation-specific recombinant proteins as positive controls in your assay.

Which checkpoint antibodies are best for melanoma TIL analysis?

For tumor-infiltrating lymphocyte characterization, we recommend our anti-PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3 antibodies. These are available as unconjugated or can be custom-conjugated for flow cytometry panels.

What diagnostic IHC panel do you recommend for melanoma?

A standard melanoma IHC panel includes S100 (high sensitivity), SOX10 (nuclear marker), Melan-A/MART-1 (cytoplasmic), and HMB45/gp100 (specific for melanosomes). We offer antibodies for all four markers.

Do you have tebentafusp-related reagents?

Yes — we offer a research-grade tebentafusp biosimilar and anti-gp100/HLA-A2 complex antibodies for binding characterization, competitive assays, and T-cell redirection studies.

Can I get custom antibodies for novel melanoma neoantigens?

Yes — our parent company AtaGenix provides custom antibody development from immunogen design through monoclonal antibody production, including peptide-MHC complex-targeting antibodies for immuno-oncology.

825 product results for "Melanoma"

Options+
Options
Confirm
  • Product types
    0 selected
    Biosimilars (1)
    Antibodies (251)
    Assay Kit (396)
    Research Biosimilar (141)
    Proteins (35)
  • Expression system
    0 selected
    Mammalian Cells (157)
    E. coli (20)
  • Target
    0 selected
    Alacizumab (1)
    Pembrolizumab (3)
    CD274/PD-L1 & TGFBR2 (1)
    CD366/HAVCR2/TIM-3 (1)
    CTLA4 & PD1 (2)
    Tovetumab (1)
    S100A16 (1)
    Urelumab (1)
    CD223/LAG3 & CD279/PD-1 (4)
    Tezepelumab (1)
    Ixekizumab (1)
    S100A13 (1)
    Anetumab (1)
    Blosozumab (1)
    Astegolimab (1)
    Obiltoxaximab (1)
    RBD (Omicron/BA.4/BA.5) (1)
    Panitumumab (3)
    TPP47 (1)
    Sirukumab (1)
    Atezolizumab (3)
    Spike glycoprotein (9)
    Tirzepatide (2)
    E8L (5)
    RBD (Kappa) (1)
    EPO/Erythropoietin (1)
    Aflibercept (1)
    Nesvacumab (1)
    gD/US6 (1)
    S100B (7)
    Pertuzumab (3)
    CD278/ICOS (1)
    Etanercept (3)
    CD3E (1)
    NP/Nucleoprotein (3)
    Camidanlumab (1)
    Enoblituzumab (1)
    TFF3 (1)
    Ramucirumab (1)
    Indatuximab (1)
    Sintilimab (1)
    CD47/MER6 & CD274/PD-L1 (2)
    Bimagrumab (1)
    Ipilimumab (2)
    Utomilumab (1)
    CD274/PD-L1/B7-H1 (1)
    Ivuxolimab (1)
    Vofatamab (1)
    Remtolumab (1)
    CD274/PD-L1 & CD28 & CD152/CTLA4 (1)
    CD274/PD-L1 & SLT-Ia (1)
    Itolizumab (1)
    Anifrolumab (1)
    Romosozumab (1)
    Iscalimab (1)
    Daclizumab (1)
    Emibetuzumab (1)
    TRP-1 & CD3e (1)
    Serclutamab (1)
    G/Major surface glycoprotein G (1)
    Ziltivekimab (1)
    TDP2 (1)
    Carlumab (1)
    Avelumab (3)
    TRP-1 & CD134/OX40 (1)
    Spike Protein (Trimer) (2)
    Benufutamab (1)
    GP/Envelope glycoprotein (4)
    Lenzilumab (1)
    Semorinemab (1)
    A35R (5)
    RBD (Delta Plus) (1)
    CD366/TIM-3 (31)
    Certolizumab (2)
    Cixutumumab (1)
    Andecaliximab (1)
    Suvizumab (1)
    Vanucizumab (1)
    US8/gE (1)
    Trastuzumab (2)
    Obinutuzumab (2)
    Sarilumab (2)
    gp100 peptide-HLA Complex (1)
    RBD (Omicron/JN.1) (1)
    Varisacumab (1)
    Belantamab (1)
    Mirzotamab (1)
    FLT1/VEGFR1 & CD274/PD-L1 (1)
    Tislelizumab (1)
    CD86/B7-2 (25)
    CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)
    Tremelimumab (1)
    Magrolimab (1)
    CD80/B7-1 & CD86/B7-2 (2)
    Elezanumab (1)
    Pogalizumab (1)
    Secukinumab (2)
    CD274/PD-L1 & VEGFA (1)
    Ontamalimab (1)
    T3E (1)
    RBD (Omicron/KP.2) (1)
    Gremubamab (1)
    VSIR/VISTA & CD274/PD-L1 (1)
    Elotuzumab (1)
    Fluorescein & CD274/PD-L1 (1)
    N/Nucleoprotein (1)
    DCT (1)
    Durvalumab (3)
    NP/Nucleocapsid (5)
    Conatumumab (1)
    gG/US4 (2)
    Namilumab (1)
    Tilavonemab (1)
    IL6 (1)
    TYRP1 (2)
    Semaglutide (2)
    Infliximab (2)
    BRAF/B-Raf (4)
    Dalotuzumab (1)
    CD274/PD-L1 & CD3E (1)
    Sotrovimab (1)
    Spike glycoprotein E2 (2)
    Zanidatamab (1)
    Afutuzumab (1)
    Varlilumab (1)
    Teclistamab (1)
    SOX10 (2)
    HLA-A2-peptide (ITDQVPFSV) Complex (4)
    Omburtamab (1)
    Ascrinvacumab (1)
    Lintuzumab (1)
    Toripalimab (1)
    Daratumumab (3)
    Zalifrelimab (1)
    S100A10 (1)
    Tavolimab (1)
    Oxelumab (1)
    CD366/TIM-3 & CD279/PD-1 (2)
    Cusatuzumab (1)
    Icrucumab (1)
    Ustekinumab (3)
    PMEL17/ME20M (7)
    T-cell surface antigen T3/Leu-4 epsilon chain (1)
    CD274/PD-L1 (72)
    CD340/ERBB2 (1)
    Ibalizumab (1)
    Tocilizumab (3)
    S100A2 (1)
    RBD (WT) (1)
    Tesidolumab (1)
    Cergutuzumab (1)
    Lorvotuzumab (1)
    Pacmilimab (1)
    CD279/PD-1 & CD274/PD-L1 (1)
    Rituximab (1)
    Drozitumab (1)
    gB/Envelope glycoprotein B (1)
    Otilimab (1)
    Zagotenemab (1)
    S100A8 (1)
    Eculizumab (3)
    Evolocumab (1)
    Figitumumab (1)
    Farletuzumab (1)
    Foravirumab (1)
    CD274/PD-L1 & CD47/MER6 (1)
    Casirivimab (1)
    Lupartumab (1)
    S100A5 (4)
    Spike glycoprotein E1 (2)
    NRAS (1)
    Epcoritamab (1)
    Glembatumumab (1)
    Crizanlizumab (1)
    HLA-A2-peptide (YLEPGPVT) Complex (4)
    Sibrotuzumab (1)
    CD80/B7-1 (17)
    CD274/PD-L1 & CD137/TNFRSF9 (1)
    Enfortumab (1)
    Lirilumab (1)
    Tibulizumab (1)
    EGFR & CD3E & PD-L1 & 4-1BB (1)
    S100A9 (2)
    Vorsetuzumab (1)
    Ieramilimab (1)
    Glofitamab (1)
    Mirikizumab (2)
    TRP-1 & CD47/MER6 (1)
    T-cell surface glycoprotein CD3 epsilon chain (1)
    IL1RL1/ST2 (1)
    Tregalizumab (1)
    CD223/LAG3 (35)
    A29L (6)
    RBD (Alpha) (1)
    Labetuzumab (1)
    CD152/CTLA4 & CD274/PD-L1 (1)
    Lexatumumab (1)
    gE/Envelope glycoprotein E (1)
    TIGIT & CD274/PD-L1 (1)
    Alirocumab (1)
    Canakinumab (1)
    MLANA (1)
    Ganitumab (1)
    Mirvetuximab (1)
    Rafivirumab (1)
    CD274/PD-L1 & CD134/OX40 (1)
    Imdevimab (1)
    dsRNA (1)
    CD117/KIT (23)
    Zenocutuzumab (1)
    S100A14 (1)
    Balstilimab (1)
    CD274/PD-L1 & CD152/CTLA4 (1)
    Talacotuzumab (1)
    Inclacumab (1)
    Pasotuxizumab (1)
    HLA-A2-peptide (KTWGQYWQV) Complex (2)
    Frovocimab (1)
    CD274/PD-L1 & TGFBR2/TGFR-2 (1)
    Cinpanemab (1)
    Oleclumab (1)
    CD152/CTLA4 & CD279/PD-1 (1)
    Ifabotuzumab (1)
    Edrecolomab (1)
    Simlukafusp Alfa (1)
    Golimumab (3)
    HLA-A2-peptide (TDQVPFSV) Complex (1)
    Vunakizumab (1)
    CD366/TIM-3 & CD274/PD-L1 (1)
    MITF (1)
    ATP7B (1)
    Ibritumomab (1)
    S100a15a (1)
    Omalizumab (2)
    dsDNA (1)
    Zanolimumab (1)
    Lacnotuzumab (1)
    M1R (5)
    p-Tyr (1)
    RBD (Beta) (1)
    Tanezumab (1)
    S100A12 (1)
    Tisotumab (1)
    Nirsevimab (1)
    Natalizumab (2)
    Tigatuzumab (1)
    gD/Envelope glycoprotein D (1)
    Milatuzumab (1)
    Befovacimab (1)
    Denosumab (3)
    CD175/Tn (10)
    B6R/SL-159 (1)
    Gevokizumab (1)
    Teprotumumab (1)
    Bevacizumab (3)
    sCD14 (1)
    Depatuxizumab (1)
    CD137/4-1BB & CD274/PD-L1 (3)
    Meplazumab (1)
    Mazdutide (2)
    Mavezelimab (1)
    Cetrelimab (1)
    CD279/PD-1 & CD152/CTLA4 (4)
    Vibecotamab (1)
    Rosopatamab (2)
    Lodelcizumab (1)
    Afasevikumab (1)
    CD19 & PD-L1 & CD3E & CD137 (1)
    S100P (1)
    Ianalumab (1)
    S100A4 (2)
    Codrituzumab (1)
    F/Fusion glycoprotein F0 (5)
    Losatuxizumab (1)
    TPP15 (1)
    Clazakizumab (1)
    Mosunetuzumab (1)
    Dilpacimab (1)
    RBD (6)
    Glycoprotein (5)
    RBD (Gamma) (1)
    Spike glycoprotein (RBD) (1)
    Cabiralizumab (1)
    Palivizumab (3)
    gC/Envelope glycoprotein C (1)
    Concizumab (1)
    Cetuximab (3)
    SARS-CoV-2 Neutralization Antibody (3)
    Brolucizumab (1)
    Tosatoxumab (1)
    CD274/PD-L1 & CD28 (1)
    S100A6 (1)
    S100A11 (1)
    Favezelimab (1)
    Nivolumab (3)
    CD223/LAG3 & CD152/CTLA4 (1)
    Olaratumab (1)
    Tarextumab (1)
    Calprotectin (S100A8/9) (3)
    CD79B (2)
    Zampilimab (1)
    Bimekizumab (1)
    CD274/PD-L1 & CD279/PD-1 (1)
    S100A1 (2)
    Letolizumab (1)
    Rolinsatamab (1)
    Amatuximab (1)
    Dupilumab (3)
    PDL1 & VEGF (1)
    Tiragolumab (2)
    Guselkumab (2)
    Necitumumab (1)
    TPP17 (1)
    IDO1 (2)
    Olokizumab (1)
    Ocaratuzumab (1)
    Navicixizumab (1)
    RBD (Delta) (3)
    M/Matrix protein (2)
    LAG3 & PD-1 (1)
    Eldelumab (1)
    Sacituzumab (1)
    H3L (3)
    RBD (E484K) (1)
    Adalimumab (3)
    Emactuzumab (1)
    CD152/CTLA4 & CD134/OX40 (1)
    Imalumab (1)
    Suptavumab (1)
    Asp f 1/mitF (1)
    Romiplostim (2)
    Faricimab (1)
    gC/UL44 (1)
    Disitamab (1)
    CD152/CTLA4 (75)
    Marstacimab (1)
    RBD (Omicron/BA.5) (3)
    Basiliximab (1)
    Apamistamab (1)
    Ranibizumab (3)
  • Species
    0 selected
    Dog (2)
    Mus musculus (Mouse) (5)
    Homo sapiens (Human) (3)
    Tupaia chinensis (2)
    Canis lupus familiaris (1)
    Felis catus (Cat) (4)
    Human (156)
    Mouse (16)
    Canis lupus familiaris (Dog) (4)
  • Applications
    0 selected
    Research in vivo (1)
    in vivo CTLA-4 neutralization (1)
    FuncS (17)
    Blocking (2)
    in vivo intra-tumoral regulatory T cell depletion (1)
    IHC (63)
    FCM (138)
    IP (1)
    Neutralization (2)
    SDS-PAGE (35)
    ELISA (715)
    Immunogen (35)
    Bioactivity: FACS (139)
    IFA (4)
    FACS (3)
    IF (3)
    Bioactivity testing in progress (16)
    Functional assay (142)
    GICA (2)
    Functional assay (3)
    SPR (3)
    Research in vivo (142)
    in vivo (2)
    WB (101)
  • Reactivity
    0 selected
    Monkey (5)
    Cyprinus carpio (1)
    Rat (16)
    Monodelphis domestica (1)
    Callithrix jacchus (1)
    Bos taurus (8)
    Danio rerio (1)
    Oryzias latipes (1)
    Homo sapiens (Human) (1)
    Capra hircus (1)
    Macaca mulatta (1)
    Oryctolagus cuniculus (4)
    Pig (5)
    Drosophila grimshawi (1)
    Xenopus laevis (1)
    Cat (1)
    Avian retrovirus IC10 (1)
    B7-H1 / PD-L1 / CD274 (1)
    Drosophila willistoni (1)
    Avian rous-associated virus type 1 (1)
    Broad-Spectrum (1)
    Kirsten murine sarcoma virus (1)
    Human (172)
    Dog (12)
    Coturnix japonica (1)
    Mouse (66)
    Kryptolebias marmoratus (1)
    Chicken (4)
    Pongo abelii (2)
    Tupaia chinensis (2)
    Bovine (1)
    Carassius auratus (1)
    Neosartorya fumigata (1)
    Limanda limanda (1)
    Cavia porcellus (1)
    Mesocricetus auratus (1)
  • Host species
    0 selected
    Human (143)
    Mouse (132)
    Rat (10)
    Alpaca (5)
    Chimeric (5)
    Dog (2)
    Armenian Hamster (5)
    Rabbit (53)
    Humanized (34)
  • Clonality
    0 selected
    Monoclonal (341)
    Polyclonal (47)
  • Conjugate
    0 selected
    Unconjugated (244)
    PerCP (27)
    PE (27)
    FITC (27)
    APC (27)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only